# Paclitaxel

## FORMOXOL inj 60mg/10mL

##### 

| TAH Drug Code      | IFOR10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | Premedication with dexamethasone 20 mg orally at 12 and 6 hours prior to paclitaxel, promethazine 25 or 50 mg or diphenhydromine 50 mg IV 30-60 minutes prior to paclitaxel, and cimetidine 300 mg, ranitidine 50 mg or famotidine 20 mg IV 30-60 minutes prior to paclitaxel is recommended.Baseline neutrophil count should be ?1,500 cells/mm3 (1.5 x 10^9 cells/L), platelets should be ?100,000 cells/mm3 (100 x 10^9 cells/L) prior to treatment. [Ovarian Caner, advanced]- Previously untreated: 175 mg/m2 infused over 3 hours every 3 weeks in combination with cisplatin 75 mg/m2 or 135 mg/m2 over 24 hours administered every 3 weeks in combination with cisplatin 75 mg/m2.- Previously treated: 135 or 175 mg/m2 infused over 3 hours every 3 weeks.  [Breast Cancer]- Adjuvant treatment: 175 mg/m2 infused over 3 hours every 3 weeks for 4 cycles (administer sequentially following an anthracycline-containing regimen).- Breast cancer, metastatic or relapsed: 175 mg/m2 infused over 3 hours every 3 weeks. [Non-small cell lung cancer (NSCLC)] 135 mg/m2 infused over 24 hours every 3 weeks in combination with cisplatin 75 mg/m2. [Kaposi sarcoma, AIDS related] 135 mg/m2 over 3 hours every 3 weeks or 100 mg/m2 over 3 hours every 2 weeks (due to dose-related toxicity, the 100 mg/m2 dose should be used for patients with a lower performance status). |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to paclitaxel, polyoxyl 35/polyoxyethylated castor oil (Cremophor EL), or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts <1,500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts <1,000/mm3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Bone marrow suppression, peripheral neuropathy, GI disturbances, alopecia, hypersensitivity. Dermatologic: Alopecia (55% to 96% ) Gastrointestinal: Diarrhea (16% to 90% ), Inflammatory disease of mucous membrane (5% to 45% ), Nausea and vomiting, Any grade (9% to 88% ) Hematologic: Anemia, Any grade (47% to 96% ), Leukopenia (90% ), Neutropenia, Any grade (78% to 100% ), Thrombocytopenia, Any grade (4% to 68% ) Immunologic: Immune hypersensitivity reaction, Any grade (2% to 45% ) Musculoskeletal: Arthralgia, Myalgia Neurologic: Peripheral neuropathy, Any grade (42% to 79% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

## Formoxol inj 30mg/5mL

##### 

| TAH Drug Code      | IFORM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | Premedication with dexamethasone 20 mg orally at 12 and 6 hours prior to paclitaxel, promethazine 25 or 50 mg or diphenhydromine 50 mg IV 30-60 minutes prior to paclitaxel, and cimetidine 300 mg, ranitidine 50 mg or famotidine 20 mg IV 30-60 minutes prior to paclitaxel is recommended.Baseline neutrophil count should be ?1,500 cells/mm3 (1.5 x 10^9 cells/L), platelets should be ?100,000 cells/mm3 (100 x 10^9 cells/L) prior to treatment. [Ovarian Caner, advanced]- Previously untreated: 175 mg/m2 infused over 3 hours every 3 weeks in combination with cisplatin 75 mg/m2 or 135 mg/m2 over 24 hours administered every 3 weeks in combination with cisplatin 75 mg/m2.- Previously treated: 135 or 175 mg/m2 infused over 3 hours every 3 weeks.  [Breast Cancer]- Adjuvant treatment: 175 mg/m2 infused over 3 hours every 3 weeks for 4 cycles (administer sequentially following an anthracycline-containing regimen).- Breast cancer, metastatic or relapsed: 175 mg/m2 infused over 3 hours every 3 weeks. [Non-small cell lung cancer (NSCLC)] 135 mg/m2 infused over 24 hours every 3 weeks in combination with cisplatin 75 mg/m2. [Kaposi sarcoma, AIDS related] 135 mg/m2 over 3 hours every 3 weeks or 100 mg/m2 over 3 hours every 2 weeks (due to dose-related toxicity, the 100 mg/m2 dose should be used for patients with a lower performance status). |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to paclitaxel, polyoxyl 35/polyoxyethylated castor oil (Cremophor EL), or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts <1,500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts <1,000/mm3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Bone marrow suppression, peripheral neuropathy, GI disturbances, alopecia, hypersensitivity. Dermatologic: Alopecia (55% to 96% ) Gastrointestinal: Diarrhea (16% to 90% ), Inflammatory disease of mucous membrane (5% to 45% ), Nausea and vomiting, Any grade (9% to 88% ) Hematologic: Anemia, Any grade (47% to 96% ), Leukopenia (90% ), Neutropenia, Any grade (78% to 100% ), Thrombocytopenia, Any grade (4% to 68% ) Immunologic: Immune hypersensitivity reaction, Any grade (2% to 45% ) Musculoskeletal: Arthralgia, Myalgia Neurologic: Peripheral neuropathy, Any grade (42% to 79% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

